Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 8/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837567 | 0.79 | HTR2A (0.65) | LRRK2ARHTR2AKCNH2SLC6A4 | |
| SCHEMBL20155262 | 0.78 | AR (0.51) | LRRK2ARSLC6A4EPAS1 | |
| SCHEMBL25355415 | 0.78 | AR (0.55) | LRRK2ARHTR2AKCNH2SLC6A4 | |
| SCHEMBL4376339 | 0.78 | AR (0.55) | LRRK2ARHTR2AKCNH2SLC6A4 | |
| SCHEMBL29502034 | 0.78 | ALDH1A1 (0.50) | ARSLC6A4 | |
| SCHEMBL178452 | 0.78 | ALDH1A1 (0.50) | ARSLC6A4 | |
| SCHEMBL8826047 | 0.78 | AR (0.56) | LRRK2ARSLC6A4EPAS1MRGPRX4 | |
| SCHEMBL16453433 | 0.77 | LRRK2 (0.48) | LRRK2ARHTR2AKCNH2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6476027 | 0.76 | ALDH1A1 (0.48) | ARSLC6A4 | |
| SCHEMBL12216024 | 0.75 | AR (0.50) | ARHTR2AKCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981851-B1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| CN-101415685-B | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC | 2011-08-24 | — | — | CN | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| CN-101415685-A | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | CN | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | MAP3K1, MAP3K19, MAP3K20 | LRRK2 670/4885AR 3132/4885HTR2A 4192/4885 |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | MAP3K19, MAP3K2, MAP3K20 | LRRK2 766/4885AR 2369/4885HTR2A 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.